Table 2:

Summary of results, mean ± SD

Enhancing AreasPerilesional HyperintensityNAWMPaPb95% CI
ADCc
    TDLs0.83 ± 0.151.56 ± 0.110.76 ± 0.06.02d.810.74–0.92
    High-grade gliomas1.01 ± 0.251.54 ± 0.20.79 ± 0.060.90–1.13
pc
    TDLs1.44 ± 0.262.7 ± 0.191.31 ± 0.10.02d.811.29–1.59
    High-grade gliomas1.76 ± 0.442.67 ± 0.341.37 ± 0.111.56–1.96
qc
    TDLs0.25 ± 0.070.36 ± 0.050.55 ± 0.06.004d.550.21–0.30
    High-grade gliomas0.33 ± 0.070.38 ± 0.070.54 ± 0.070.30–0.37
Lc
    TDLs1.46 ± 0.262.7 ± 0.181.43 ± 0.11.016d.831.31–1.62
    High-grade gliomas1.79 ± 0.432.7 ± 0.341.46 ± 0.091.60–1.99
FA
    TDLs0.21 ± 0.060.44 ± 0.330.47 ± 0.07.341.0520.17–0.25
    High-grade gliomas0.23 ± 0.060.51 ± 0.090.45 ± 0.060.20–0.27
rCBV
    TDLs2.11 ± 1.12.003d1.47–2.76
    High-grade gliomas3.77 ± 1.653.02–4.52
  • a Difference in the mean values of enhancing areas of TDLs and high-grade gliomas.

  • b Difference in the mean values of perilesional hyperintensity of TDLs and high-grade gliomas.

  • c Values of ADC, p, q, and L are in units of 10−3 mm2/s.

  • d Significant.